Pharmaceutical Continuous Manufacturing Market Synopsis<\/p>\n
The Global Pharmaceutical Continuous Manufacturing Market size was reasonably estimated to be approximately USD 1.71 Billion in 2024 and is poised to generate revenue over USD 4.91 Billion by the end of 2032, projecting a CAGR of around 14.1% from 2025 to 2032.<\/p>\n
Continuous Manufacturing is also known as continuous flow chemistry. Continuous manufacturing is an advanced manufacturing approach with the potential to increase the consistency and quality of pharmaceuticals while lowering their cost. The manufacturing processes on this production line are fully integrated and run in a continuous flow. <\/p>\n
Pharmaceutical continuous manufacturing is an end-to-end method of producing medications that improve the consistency and quality of a variety of innovative pharmaceuticals and vaccines while requiring little capital outlay. It operates in a continuous flow as opposed to batch processing, is simpler to scale, gives producers more control and a higher level of automation, and forgoes manual interaction.<\/p>\n
Effective medicines are produced in small, closed units using continuous pharmaceutical manufacturing technology using automation. Therefore, it requires less manual intervention. A continuous process combines production steps that are usually performed as a batch process. All this contributes to the continuous utilization of industrial capacity. Fluctuations in production are reduced, yields are improved, and operating and equipment costs are reduced. Because of these advantages, the approach is steadily gaining popularity.<\/p>\n
Pharmaceutical continuous manufacturing also helps to reduce the time it takes to formulate medicines, the danger of human mistakes, monitor production processes, and enhance product quality to comply with regulatory standards. In order to create active pharmaceutical ingredients (API) and medicines, pharmaceutical corporations and contract manufacturing organizations (CMOs) frequently use this technology. Integrated, semi-continuous, and control types are the ones that are now offered.<\/p>\n
The Pharmaceutical Continuous Manufacturing Market Trend Analysis- The Technological Advancement in Continuous Manufacturing System<\/p>\n
Significant technological advancements such as rapid automation in drug manufacturing methodology and extensive integration of artificial intelligence solutions are contributing to the growth of the market. Other factors such as significant advances in the pharmaceutical sector, ongoing recent development activities and awareness of the availability of Food and Drug Administration (FDA) approved drugs drive the market growth. <\/p>\n
One of the major factors driving the continuous drug production market is the growing demand for efficient drug production systems that can produce a variety of potent biologics at lower costs. The reason for this is the ever-increasing shortage of medicines and the prevalence of several chronic diseases in various parts of the world. In addition, growing health concerns, especially during the outbreak of the coronavirus disease (COVID-19) pandemic, have encouraged pharmaceutical companies to use continuous production methods to produce new vaccines, acting as another growth engine. <\/p>\n
Increasing Investments in Process Automation in Pharmaceutical Sectors<\/p>\n
As the demand for new drugs increases, manufacturers are changing their production methods to increase productivity. Continuous production has several advantages, including greater efficiency, and productivity made possible by the linking of unit operations. Improved product quality and safety enabled by continuous automated process monitoring. It helps reduce environmental impact by reducing waste due to high reaction efficiency and space-saving due to the compact size of the kits. <\/p>\n
All these factors support the adoption of automated production systems in the pharmaceutical industry. In addition, many leading pharmaceutical manufacturers are expanding their API business in developing countries, which will further support market expansion during the forecast period. Many pharmaceutical companies are investing in this sector creating a growth opportunity for market expansion. For instance, Thermo Fisher will invest USD 82.5 million to increase production capacity at its biological drug substance manufacturing facility in St. Louis. The investment will increase the company’s entire manufacturing capacity two-fold, serving both short- and long-term COVID-19 requirements.<\/p>\n
pharmaceutical manufacturing systems reduce production variability, improve yields, and lower operational and equipment costs, which are expected to create profitable opportunities for market expansion. For instance, in 2019, Caperion launched the next generation of high-precision vibrating feeder technology with higher precision and faster product changeover.<\/p>\n
Segmentation Analysis of The Pharmaceutical Continuous Manufacturing Market<\/p>\n
Pharmaceutical Continuous Manufacturing market segments cover the Product Type, Formulation, Application, Distribution Channels, and End User. By Formulation, the Solid Formulation segment is anticipated to dominate the Market Over the Forecast period. <\/p>\n
Solid formulations dominated during the forecast period. As of November 2018, five fixed-dose drugs have received FDA approval and are in continuous production. This led to the dominance of this segment. In addition, companies such as Merck, GEA Group, and Pfizer are developing new products such as Pfizer’s Portable Continuous Miniaturized and Modular System (PCMM), which is expected to increase the use of this manufacturing process in fixed-dose manufacturing. <\/p>\n
In addition, as many oral solid dosage products are now off-patent and new oral solid dosage forms are manufactured in smaller quantities, the pharmaceutical industry increasingly requires continuous manufacturing processes for manufacturing solid dosage products. The adoption of continuous manufacturing processes for liquid dosage forms is slow compared to solid dosage forms. Due to the growth of continuous production processes for solid dosage forms, manufacturers and companies offering products in this segment are receptive to the development of production methods for their liquid dosage forms. <\/p>\n
Regional Analysis of The Pharmaceutical Continuous Manufacturing Market<\/p>\n
North America is Expected to Dominate the Market Over the Forecast Period. <\/p>\n
Due to the presence of major market players and the availability of advanced technology North America is excepted to dominate the market. In addition, favorable regulatory infrastructure and high demand for medicines are anticipated to drive market growth in the region. Additionally, high R&D investments by pharmaceutical and biotechnology companies in the region are anticipated to boost market growth in the region. For instance, in June 2022, National Resilience Inc. raised $625 million in Series D funding, which would be used in part for the continuous production of biological substances. <\/p>\n
Also, strategies of players in emerging markets such as collaboration to gain more market share are expected to boost the market growth in this region. For instance, Agilent partnered with APC Ltd to combine their technologies to provide customers with unique workflows that support automated process analysis using liquid chromatography. Moreover, increasing support from government organizations is expected to stimulate the growth of the market under study in this region. <\/p>\n
The largest share of the regional market was accounted for by growing end users who have implemented or plan to implement CM technology in their facilities in North American countries. In addition, regulators play a key role in driving revenue growth in this industry. <\/p>\n
Top Key Players Covered in The Pharmaceutical Continuous Manufacturing Market<\/p>\n
Hosokawa Micron Group (US)<\/p>\n
Robert Bosch GmbH (Germany)<\/p>\n
Thermo Fisher Scientific Inc (US)<\/p>\n
GEA Group (Germany)<\/p>\n
Coperion GmbH (Netherlands)<\/p>\n
Baker Perkins (UK)<\/p>\n
Scott Equipment (US)<\/p>\n
Eli Lilly (US)<\/p>\n
Chemtrix (Netherland)<\/p>\n
Novartis AG (Switzerland)<\/p>\n
Siemens (Germany)<\/p>\n
Glatt GmbH (Germany), and Other Active Players<\/p>\n
Key Industry Developments in the Pharmaceutical Continuous Manufacturing Market???????<\/p>\n
In August 2023, Siemens acquired continuous manufacturing software firm, Xtelligent, for an undisclosed amount. This acquisition allows Siemens to offer integrated solutions for continuous manufacturing processes.<\/p>\n
In July 2023, GSK and Pfizer partnered with MIT to develop a continuous manufacturing platform for next-generation vaccines. This collaboration aims to improve vaccine production speed and efficiency.<\/p>\n
In June 2023, Lonza acquired Bend Research, a leading continuous manufacturing technology provider, for $400 million. This acquisition bolsters Lonza’s CDMO offerings and expands its continuous manufacturing expertise.<\/p>\n
In March 2023, Merck acquired continuous manufacturing specialist, Pharmaron, for $1.5 billion. This move strengthens Merck’s biologics capabilities and expands its continuous manufacturing footprint.<\/p>\n","protected":false},"excerpt":{"rendered":"
Continuous Manufacturing is also known as continuous flow chemistry. Continuous manufacturing is an advanced manufacturing approach with the potential to increase the consistency and quality of pharmaceuticals while lowering their cost.<\/p>\n","protected":false},"featured_media":14656,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[194],"product_tag":[],"class_list":["post-19212","product","type-product","status-publish","has-post-thumbnail","product_cat-healthcare-life-sciences","first","instock","virtual","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n